Background
Methods
Literature search
Data extraction
Analysis
Results
First author publication year [reference] | Country | Disease area/study population | Floora > 15% | Missing ≥ 5% | Test–retest ICC, Cohen’s kappa (κ)c | Known-group validityb |
---|---|---|---|---|---|---|
Musculoskeletal diseases and orthopedic patients | ||||||
Buchholz 2015 [A23] | GER | Orthopedic, psychosomatic, rheumatologic rehabilitation patients | No | No | ||
Conner-Spady 2015 [A24] | CA | Osteoarthritis, referred for total joint replacement | No | No | ICC Index: excellent Kappa: MO good; SC excellent; UA good; PD good; AD excellent | |
Greene 2015 [A29] | USA | Patients undergoing total hip arthroplasty | No | |||
Whitehurst 2016 [A56] | CA | Spinal cord injury | MO & SC | |||
Bilbao 2018 [A68] | ESP | Hip or knee osteoarthritis | No | No | Statistically sign. difference across WOMAC scores and self-rated health | |
Cheung 2018 [A72] | CN | Patients attending a back pain clinic | No | No | Statistically sign. over disc degeneration and spinal surgery, but not other spine-related factors or pain | |
Conner-Spady 2018 [A73] | Manitoba, CA | Osteoarthritis; 1 year following total joint replacement | No | ICC: excellent | ||
Diabetes | ||||||
Pan 2014 [A34] | CN | Outpatients with type 2 diabetes mellitus | No | |||
Pattanaphesaj 2015 [A35] | TH | Diabetes; treated with insulin | No | No | ICC: good Kappa: MO fair; SC nr; UA fair; PD fair; AD fair | |
Wang 2015 [A42] | SG | Type II diabetes | No | |||
Wang 2016 [A55] | SG | Diabetes | No | |||
McClure 2018 [A87] | CA | Type II diabetes | No | |||
Cancer | ||||||
Kim 2012 [A2] | Korea | Cancer patients receiving ambulatory chemotherapy | No | ICC: excellent Kappa: MO good; SC good; UA fair; PD fair; AD fair | ||
Lee 2013 [A9] | SG | Histologically confirmed breast cancer | Across Oncologist, Patient evaluated performance status, treatment mode, and evidence of disease | |||
Kouwenberg 2019 [A98] | NL | Breast reconstruction/mastectomy patients | Across radiotherapy type, surgery group and age | |||
Skin diseases | ||||||
Swinburn 2013 [A12] | UK | Psoriasis | Trending as expected across skin-specific questionnaires (DLQI and SAPAPSI) | |||
Poor 2017 [A63] | HU | Psoriasis | No | No | Not sign. across age groups, but sign. across gender. | |
Yfantopoulos (2017a) [A64] | GR | Psoriasis | No | |||
Tamasi 2018 [A90] | HU | Pemphigus vulgaris and pemphigus foliaceus | Statistically sign. across severity of disease, symptoms and comorbidities. Not across gender or treatment status | |||
Stroke | ||||||
Golicki 2015 [A27] | PL | Stroke | No | Trends as expected across age, modified Rankin Scale, Barthel Index, Stroke type | ||
Golicki 2015 [A28] | PL | Stroke | MO, SC, UA at baseline | No | ||
Chen 2016 [A46] | Taiwan | Stroke | Only SC | |||
Mental health diseases | ||||||
Mihalopoulos 2014 [A20] | AU, UK, USA, CN, NOR, GER | People reporting depressive symptoms [MIC]e | Strongly across levels of depression | |||
Camacho 2018 [A70] | UK | Mental health conditions | No | |||
Engel 2018 [A77] | AU, CA, GER, NOR, UK, USA | Depression [MIC]e | Statistically sign. between healthy and depressive samples: effect size is large | |||
Cardiovascular diseases | ||||||
White 2015 [A43] | UK | Symptomatic cardiac arrhythmia before and after cardiac ablation | ICC: excellent | |||
Chuang 2019 [A94] | FR, AT, GER, I, ESP, CH, UK | Acute pulmonary embolism or deep vein thrombosis | No | No | Moderately across embolism types | |
Gao 2019 [A96] | AU, CA, GER, NOR, UK, US | Heart disease | Statistically sign. differences across age, gender, education and MacNew Heart Disease scores | |||
Lung diseases | ||||||
Lin 2014 [A19] | USA | Chronic obstructive pulmonary disease | ||||
Szentes 2018 [A89] | GER | Interstitial lung diseases | No | |||
Hernandez 2019 [A97] | UK, FR | Asthma | Moderately to strongly with medication use and asthma control | |||
Liver diseases | ||||||
Scalone 2011 [A1] | I | Different severe chronic hepatic diseases | No | No | ||
Scalone 2013 [A10] | I | Chronic hepatic diseases | No | |||
Jia 2014 [A18] | CN | Inpatients with hepatitis B | No | ICC: Excellent Kappa: MO excellent; SC good; UA excellent; PD excellent; AD excellent | ||
Blood diseases | ||||||
Batt 2018 [A66] | USA | Hemophilia | Statistically sign. across age, employment, cohabitation, existence of chronic conditions and pain. Not sign. across education, BMI groups, cohabitation, Hemophilia severity, treatment type | |||
Buckner 2018 [A69] | USA | Hemophilia B and caregivers of children (< 18 years) with hemophilia B | Statistically sign. differences across self-reported anxiety, depression, arthritis, pain, age, hemophilia severity, functional status | |||
Kidney diseases | ||||||
Yang 2015 [A44] | SG | Diagnosis of End-stage renal disease on Peritoneal or hemodialysis | No | Strongly across comorbidity categories and symptoms, but weakly across dialysis adequacy, hemoglobin levels and burden | ||
Thaweethamcharoen 2018 [A91] | TH | Patients on peritoneal dialysis | ||||
Central nervous system diseases | ||||||
Garcia-Gordillo 2014 [A16] | ESP | Parkinson’s disease | No | |||
Fan 2018 [A78] | UK | Parkinson’s Disease | No | |||
Other patient types and studies that incorporate several disease groups | ||||||
Tran 2012 [A3] | VN | Diagnosis of HIV/AIDS | No | |||
van Hout 2012 [A4] Janssen 2013 [A6] | DK, UK, NL, PL, I, SCO | Crosswalk studyd | No | No | Moderately with age and smoking, not with education | |
Craig 2014 [15] | USA | Patients with chronic conditions from a national representative sample of adults | No | |||
Richardson 2015 [A37] Mitchell 2015 [A31] | AU, CA, GER, NOR, UK, USA | MIC studye | Strongly across different chronic disease groups vs. healthy | |||
Sakthong 2015 [A39] | TH | Outpatient patients taking continuous medication at least 3 months for 14 disease groups | No | ICC index: excellent Kappa: MO good; SC fair; UA fair; PD fair; AD fair | Statistically sign. across age, gender, education, employment, self-rated health, comorbidities, number of medicines and perception of disease control | |
Lamu 2016 [A49] | AU, CA, GER, NOR, UK, USA | MIC studye | Weakly with subjective well-being | |||
Rogers 2016 [A54] | UK | Deaf persons using British sign language | No | ICC: excellent Kappa: MO good; SC fair; UA fair; PD good; AD fair | Weakly to moderately with CORE 10, CORE 6D | |
Fermont 2017 [A59] | UK | Severe and complex obesity; undergoing bariatric surgery | Not statistically sign. across BMI levels (Above and under 50) or those with comorbidities versus those without. | |||
Bewick 2018 [A67] | UK | Chronic rhino sinusitis patients | No | |||
Easton 2018 [A75] | AU | Older residents of care facilities with dementia or cognitive impairments and proxies | Moderate to small differences across cognition scores and modified Barthel index categories | |||
Janssen 2018 [A83] | PL, DK, England, I, SCO, NL | Crosswalk studyd | Only UA | |||
Kohler 2018 [A84] | India | Post vaginal birth or cesarean section | MO, SC, UA only at baseline | |||
Gandhi 2019 [A95] | SG | Cataract surgery | No | |||
Rencz 2019 [A99] | HU | Crohn’s disease | No | No | Statistically sign. differences across age groups and chronic conditions | |
General population | ||||||
Kim 2013 [A8] | KOR | Nationally representative general population | ICC: excellent Kappa: MO good; SC poor; UA good; PD fair; AD poor | |||
Agborsangaya 2014 [A13] | CA | General population | No | No | ||
Hinz 2014 [A17] | GER | General population | No | |||
Feng 2015 [A25] | England | General population | No | |||
Mulhern 2015 [A32] | UK (Yorkshire) | General adult population | No | |||
Scalone 2015 [A40] | I | General population; quota sampling | No | |||
Augustovski 2016 [A45] | Uruguay | General population; sampling quotas by location | No | |||
Ferreira 2016 [A47] | Portugal | Students from 2 universities aged 30 years or under | No | No | Statically sign. across gender, health condition, labor situation, marital status | |
McCaffrey 2016 [A50] | AU | South Australian general population | No | |||
Oremus 2016 [A52] | CA | Toronto area general population | No | |||
Huber 2017 [A60] | GER | General population | No | |||
Konnopka 2017 [A61] | GER | General population | Each dimension sign. distinguished between categories of “dimension-specific” indicators; Index statistically sign. across age, education, diseases but not marital status | |||
Nguyen 2017 [A62] | VN (Hanoi) | Randomly selected resident adults of the city of Hanoi | No | Sign. across age, occupation, education, income, symptoms, chronic conditions; not Over health services usage | ||
Yfantopoulos 2017b [A65] | GR | General middle-aged and elderly population | No | No | Statistically sign. across age, gender and smoking status | |
Purba 2018 [A88] | Indonesia | Indonesian representative population | No | Assessed Gwet’s AC, acceptable for dimensions. ICC low (0.37) for index | Statistically sign. across age, ethnicity and gender, but not across residence, education, income or religion. | |
Hernandez 2018 [A81] | ESP | Spanish National Health Survey 2011–2012 | No | |||
Marti-Pastor 2018 [A86] | ESP | Representative general population | No | |||
Ge 2019 [A80] | SG | Young (21–44 years), middle-aged (45–64 years), older adults (≥ 65 years) | ||||
Proxies | ||||||
Bhadhuri 2017 [A57] | UK | Family members of meningitis survivors |
First author year [reference] | Patient/population group | Value set | Improved | Stable | Deteriorated | All | ||||
---|---|---|---|---|---|---|---|---|---|---|
SES | SRM | SES | SRM | SES | SRM | SES | SRM | |||
Studies using a value set for the 3L version of the EQ-5D/interim scoring method | ||||||||||
Lee 2013 [A9] | Singaporean breast cancer patients at baseline and 1 week later: regressed with self-reported performance status | Interim scoring method [A5] Japanese 3L value set | 0.54b | |||||||
Singaporean breast cancer patients at baseline and 1 week later: regressed with self-reported quality of life | 0.69b | |||||||||
Swan 2013 [A11] | Patients before and after colonoscopy screening | Interim scoring method [A5] Unclear which 3L value set was used | 0.50 | 0.44 | ||||||
Jia 2014 [A18] | Hepatitis B patients at baseline and 1 week after | Interim scoring method [A5] Chinese 3L value set | Absolute increase of 0.029–0.073 for index values for the subsample of patients with improved health. There is not enough information to calculate the SES. | |||||||
Golicki 2015 [A28] | Stoke patients initial hospitalization and 4 mo after therapy: mRS-based criterion | Interim scoring method [A5] Polish 3L value set | 0.51 | 0.69 | − 0.25 | − 0.25 | ||||
Stoke patients initial hospitalization and 4 mo after therapy: Barthel index-based criterion | 0.71 | 0.86 | − 0.40 | − 0.47 | ||||||
Chen 2016 [A46] | Stroke patients before and 3 to 4 weeks after therapy | Interim scoring method [A5] Japanese 3L value set | 0.40 | 0.63 | ||||||
Conner-Spady 2018 [A73] | Pre to 1 year post TJR (hip) | Interim scoring method [A5] UK 3L value set | 1.86 | 1.53 | ||||||
Pre to 1 year post TJR (knee) | 1.19 | 1.04 | ||||||||
Kohler 2018 [A84] | Vaginal birth 3 to 7 days postpartum | Interim scoring method [A5] UK 3L value set | 0.78a | |||||||
Vaginal birth 21 to 30 days postpartum | 1.18a | |||||||||
Cesarean Sect. 3 to 7 days postpartum | 0.90a | |||||||||
Cesarean Sect. 21 to 30 days postpartum | 1.65a | |||||||||
Gandhi 2019 [A95] | Before and after cataract surgery | Interim scoring method [A5] Singaporean & English 3L value sets | 0.25 | 0.23 | ||||||
Before and after cataract surgery | 0.26 | 0.23 | ||||||||
Studies using a value set for the 5L version of the EQ-5D | ||||||||||
Sakthong 2015 [A39] | Patients of university hospitals 1 to 2 weeks apart | Thai 5L value set | 0.33 | − 0.29 | ||||||
Nolan 2016 [A51] | COPD outpatients before and 8 weeks after pulmonary rehabilitation | English 5L value set | 0.27a | |||||||
Fermont 2017 [A59] | Patients with severe/complex obesity before and 6 mo after bariatric surgery | English 5L value set | 0.25 | 0.30a | − 0.08 | − 0.09a | 0.16 | 0.19 | ||
Bilbao 2018 [A68] | Patients with hip or knee osteoarthritis from hospital/clinic visit and 6 mo after | Spanish 5L value set | 0.40 | 0.38 | 0.05 | 0.06 | 0.39 | 0.42 | ||
Campbell 2018 [A71] | 3 mo after bariatric surgery | English 5L value set | 0.40a | |||||||
1 year after bariatric surgery | 0.32a | |||||||||
McClure 2018 [A87] | Baseline to 1 year after: longitudinal study of diabetes patients | Canadian 5L value set | 0.20 | 0.31 | 0.29 | 0.44 | ||||
Wijnen 2018 [A93] | Epilepsy patients pre intervention program to 12 mo after | Dutch and English 5L value sets | −0.017 | −0.023 | ||||||
Chuang 2019 [A94] | Baseline to 1 year after: longitudinal study of venous thromboembolism patients | English 5L value set | 0.44 | |||||||
Baseline to 1 year after: longitudinal study of venous thromboembolism patients | 0.55 | |||||||||
Studies not reporting which value set was used | ||||||||||
White 2016 [A43] | UK patients with cardiac arrhythmias pre and 8–16 weeks post catheter ablation | Not reported | − 0.22 | − 0.29 | ||||||
Bhadhuri 2017 [A57] | Non-carers of meningitis survivors 1 year apart | Not reported | 0.01 | − 0.19 | − 0.14 | |||||
Carers of meningitis survivors 1 year apart | 0.19 | − 0.02 | − 0.27 | |||||||
Carers with fewer hours of care of meningitis survivors 1 year apart | − 0.16 | 0.05 | − 0.31 |